Siolta Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Siolta Therapeutics is a biotechnology company that develops and commercializes microbiome-based therapies for the treatment of chronic diseases. Read more

Siolta Therapeutics is a biotechnology company that develops and commercializes microbiome-based therapies for the treatment of chronic diseases. Read more

Nikole Kimes's photo - Founder & CEO of Siolta Therapeutics

Founder & CEO

Nikole Kimes

CEO Approval Rating

90/100

Founded:

2016

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Second Genome is the top competitor of Siolta Therapeutics. Second Genome is headquartered in Brisbane, California, and was founded in 2009. Second Genome competes in the Biotechnology field. Second Genome generates 160% the revenue of Siolta Therapeutics.

Rebiotix is perceived as one of Siolta Therapeutics's biggest rivals. Rebiotix was founded in Roseville, Minnesota} in 2011. Like Siolta Therapeutics, Rebiotix also operates in the Biotechnology industry. Compared to Siolta Therapeutics, Rebiotix generates $2.1M less revenue.

Seres Therapeutics is seen as one of Siolta Therapeutics's top competitors. Seres Therapeutics is a Public company that was founded in Cambridge, Massachusetts in 2010. Like Siolta Therapeutics, Seres Therapeutics also works within the Biotechnology industry. Seres Therapeutics has 93 more employees vs. Siolta Therapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $5M a good estimate for Siolta Therapeutics's revenue?

Acquisitions

No recent acquisitions found related to Siolta Therapeutics

Siolta Therapeutics Funding History

$0$30M

Since Siolta Therapeutics was founded in 2016, it has participated in 3 rounds of funding. In total Siolta Therapeutics has raised $30.0M. Siolta Therapeutics' last funding round was on Sep 2020 for a total of $30.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Sep 2020
$30M

Seventure

Series A
Jun 2017
--
Seed
Dec 2016
--

Since Siolta Therapeutics was founded in 2016, it has participated in 3 rounds of funding. In total Siolta Therapeutics has raised $30.0M. Siolta Therapeutics' last funding round was on Sep 2020 for a total of $30.0M

Investments

No recent investments found related to Siolta Therapeutics

Siolta Therapeutics News

Siolta Therapeutics Press Releases

Headquarters

930 Brittan Avenue

San Carlos, California94070

415-991-0947

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Siolta Therapeutics is a biotechnology company that develops and commercializes microbiome-based therapies for the treatment of chronic diseases. Siolta Therapeutics was founded in 2016. Siolta Therapeutics' headquarters is located in San Carlos, Cali...

CEO

Siolta Therapeutics's Founder & CEO, Nikole Kimes, currently has an approval rating of 90%. Siolta Therapeutics's primary competitors are Second Genome, Rebiotix & Seres Therapeutics.

Website

sioltatherapeutics.com

Frequently Asked Questions about Siolta Therapeutics

  1. When was Siolta Therapeutics founded?

    Siolta Therapeutics was founded in 2016
  2. Who is Siolta Therapeutics's CEO?

    Siolta Therapeutics's CEO is Nikole Kimes
  3. How much revenue does Siolta Therapeutics generate?

    Siolta Therapeutics generates $5M in revenue
  4. How much funding does Siolta Therapeutics have?

    Siolta Therapeutics has historically raised $30M in funding
  1. Where is Siolta Therapeutics's headquarters?

    Siolta Therapeutics's headquarters is in San Carlos California, USA
  2. How many employees does Siolta Therapeutics have?

    Siolta Therapeutics has 15 employees
  3. What sector does Siolta Therapeutics operate in?

    Siolta Therapeutics is in Biotechnology
  4. Who are Siolta Therapeutics's competitors?

    Siolta Therapeutics's top competitors are Second Genome, Rebiotix, Seres Therapeutics